Quick Answer
Sana Biotechnology, Inc. reported Stockholders Equity of $160.88 million for the year ending 2025.
- Sana Biotechnology, Inc. showed a decrease of -35.8% in Stockholders Equity from 2024 to 2025.
- This data is from Sana Biotechnology, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$174.67 million | Q2 2020: -$260.93 million | Q3 2020: -$311.18 million | Q1 2021: $881.98 million | Q2 2021: $905.90 million | Q3 2021: $830.09 million | Q1 2022: $701.66 million | Q2 2022: $639.51 million | Q3 2022: $566.02 million | Q1 2023: $428.26 million | Q2 2023: $355.03 million | Q3 2023: $365.85 million | Q1 2024: $375.14 million | Q2 2024: $339.65 million | Q3 2024: $292.48 million | Q1 2025: $209.08 million | Q2 2025: $122.56 million | Q3 2025: $195.31 million.
- Over the full 8 years of available data (2018 to 2025), Sana Biotechnology, Inc.'s Stockholders Equity has grown by 1,319.9%.
- Historical annual values: Fiscal year 2025: $160.88 million | Fiscal year 2024: $250.50 million | Fiscal year 2023: $287.51 million | Fiscal year 2022: $499.32 million | Fiscal year 2021: $728.50 million | Fiscal year 2020: -$421.18 million | Fiscal year 2019: -$142.54 million | Fiscal year 2018: -$13.19 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: